Clinical trials: Human Abuse Potential
Cannabis Use Disorder
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam
The purpose of this study is to evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.
- Trial name
- NCT03398083
- Testing
- THC, Alprazolam, CBD
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Methamphetamine Dependence, Methamphetamine Abuse
Varenicline as a Treatment for Methamphetamine Dependence
The primary purpose of the study is to determine the effects of treatment with varenicline (1 and 2 mg daily), compared to treatment with placebo, on methamphetamine-induced craving and subjective effects in…
- Conditions
- Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
- Trial name
- Varenicline (NCT01571167)
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
General Anesthesia
Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy…
- Trial name
- NCT05614544
- Testing
- HSK3486, Propofol
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Haisco-USA Pharmaceuticals, Inc.
Abuse, Drug
A Study to Assess the Abuse Potential of Intranasal Cebranopadol
The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.
- Trial name
- NCT06453265
- Testing
- Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
General Anesthesia
Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
Part 1: To determine the doses of IV HSK3486 and propofol for use in Part 2, the abuse potential part of the study. Part 2: To evaluate the abuse potential of HSK3486 compared with propofol when administered IV to healthy…
- Trial name
- NCT07404306
- Testing
- HSK3486, propofol
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Haisco-USA Pharmaceuticals, Inc.
Healthy Volunteer
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
This randomized, placebo- and active-controlled, crossover study will evaluate the abuse liability potential of RO4917838 in recreational drug users.
- Trial name
- NCT01438749
- Testing
- RO4917838, diazepam
- Where
- United States
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Substance Use, Healthy Subjects
Abuse Potential and Human Pharmacology of Methylone
The purposes of the study are 1) To assess the abuse potential of methylone after controlled administration of a single oral dose of methylone 2) to evaluate subjective and physiological effects of methylone 3) to determine the…
- Trial name
- METI/FIS/1 (NCT05488171)
- Testing
- Methylone, 3,4-methylenedioxymethamphetamine
- Where
- Spain
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
Pain, Cannabis
Enhancing Medication-based Analgesia in Humans- STUDY 2
This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid cannabidiol (CBD; Epidiolex) would enhance analgesia, subjective reports, and…
- Conditions
- Pain, Cannabis, Opioid Use
- Trial name
- NCT04036968
- Testing
- Within-subject test of blinded study medications
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
This study will evaluate the abuse potential of ALKS 5461.
- Trial name
- NCT02413281
- Testing
- ALKS 5461, Buprenorphine
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Human Abuse Potential
Assessment of Abuse Potential of Rapastinel in Humans
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the abuse potential of single doses of rapastinel as compared with ketamine, a NMDAR antagonist that is a Schedule III dissociative…
- Trial name
- NCT03799900
- Testing
- Rapastinel, Ketamine
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Methamphetamine Dependence, Substance Abuse
Varenicline-Methamphetamine Interaction Study (2008)
The primary aim of the study is to determine the safety and tolerability of treatment with Varenicline in methamphetamine-dependent volunteers.
- Conditions
- Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
- Trial name
- NCT00733967
- Testing
- Varenicline
- Sponsor
- Baylor College of Medicine
Opioid Abuse Nondependent
Nasal Human Abuse Potential of PTI-821
The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.
- Trial name
- NCT03475862
- Testing
- PTI-821 capsule Manipulated, PTI-821 Non-manipulated, OxyContin
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Human Abuse Potential
Assessment of Abuse Potential of Cebranopadol in Humans
This study will be conducted to evaluate the abuse potential of single doses of cebranopadol as compared with oxycodone, tramadol and matching placebo in recreational drug users.
- Trial name
- NCT05256108
- Testing
- Oxycodone 40 mg, Tramadol 600 mg, Cebranopadol 600 µg
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Pain, Cannabis
Enhancing Medication-based Analgesia in Humans
This is a single-group, within-subject, double-blind, double-dummy, placebo and active-controlled study evaluated whether the FDA-approved cannabinoid dronabinol (Marinol) would enhance analgesia, subjective reports, and…
- Conditions
- Pain, Cannabis, Opioid Use, Unspecified
- Trial name
- NCT02901275
- Testing
- Within-subject test of blinded study medications
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University